Bob Duggan, Summit Therapeutics CEO (Kelly Morfopoulos via Wikimedia)

Up­dat­ed: With a promis­ing new Keytru­da con­tender, Sum­mit pre­pares to spar with Mer­ck

CHICA­GO — Sum­mit Ther­a­peu­tics is pre­pared to take on the world’s best-sell­ing drug.

On Thurs­day, the biotech’s stock near­ly tripled af­ter re­port­ing that its can­cer drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.